Oslo, 08 April 2022: In connection with the Annual General Meeting of Ultimovacs
ASA to be held on 21 April 2022, Jónas Einarsson, Chair of the Board of
Directors, has so far received proxy based voting rights without voting
instructions for 12,782,320 shares, representing 37.35% of the total voting
rights in the company.
With the addition of the 1,506,913 shares controlled by Radforsk, Jónas
Einarsson thus represents a total of 14,289,213 shares. This corresponds to
41.75% of the company's total number of shares and votes in connection with the
company's ordinary Annual General Meeting.
The proxies are only valid for the Annual General Meeting on 21 April 2022.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
For further information, please see www.ultimovacs.com
(http://www.ultimovacs.com) or contact:
Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47 90686815